Events & Presentations

Document	Type
Dec 08, 2019	Corporate Presentation 2.2 MB

More events are coming soon.

Date	Event Details
Dec 10 - Dec 14, 2019	2019 San Antonio Breast Cancer Symposium (SABCS) Supporting Materials View Presentation 1.4 MB SABCS – SOPHIA Infusion Substudy 470.9 KB
Dec 9, 2019 8:00 PM EST	MacroGenics Flotetuzumab Conference Call at ASH Listen to webcast Supporting Materials View Presentation 3.6 MB
Dec 7 - Dec 10, 2019	61st ASH Annual Meeting & Exposition Supporting Materials ASH2019-Godwin-flotetuzumab 5.9 MB ASH2019-Rutella-Flotetuzumab 7.8 MB ASH 2019 Flotetuzumab TIP 4.1 MB ASH 2019-Flotetuzumab-Clinical-Update 1 MB
Dec 3, 2019 4:15 PM EST	Evercore ISI HealthCONx Conference Listen to webcast
Nov 20, 2019 11:30 AM EST	Stifel 2019 Healthcare Conference Listen to webcast
Nov 12, 2019 11:10 AM EST	Credit Suisse 28th Annual Healthcare Conference Listen to webcast
Nov 6, 2019 4:30 PM EST	MacroGenics, Inc. Third Quarter 2019 Financial Results Conference Call Listen to webcast
Nov 6 - Nov 10, 2019	The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Supporting Materials SITC - Tumor-targeted T-cell Activation via an Investigational PD-L1 x CD137 Bispecific Molecule 2.3 MB TiP-margetuximab 708.2 KB TiP-enoblituzumab 835 KB MGA012 (anti-PD-1 mAb) anal cancer (Incyte) 337.7 KB MGA012 (anti-PD-1 mAb) cervical cancer (Incyte) 367.6 KB
Sep 27 - Oct 1, 2019	2019 European Society for Medical Oncology (ESMO) Congress Supporting Materials ESMO 2019 – Margetuximab+Pembro GEA – Clinical 1.3 MB ESMO 2019 – Margetuximab+Pembro GEA - Survival 1.3 MB ESMO 2019 – Margetuximab+Pembro GEA - Biomarker 1.2 MB
Sep 25 - Sep 28, 2019	International Cancer lmmunotherapy Conference (CICON 2019) Supporting Materials Poster Presentation 2.2 MB
Sep 4, 2019 9:30 AM EDT	Citi 14th Annual Biotech Conference Listen to webcast
Jul 31, 2019 4:30 PM EDT	MacroGenics, Inc. Second Quarter 2019 Financial Results Conference Call Listen to webcast
Jun 4, 2019 2:30 PM EDT	MacroGenics ASCO 2019 Conference Call Listen to webcast Supporting Materials MacroGenics ASCO 2019 Conference Call 2.7 MB
May 31 - Jun 4, 2019	Presentations at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Supporting Materials TiP - MGD019 (PD-1 x CTLA-4) Phase 1 Study 1 MB HER2-specific Immunity in Phase 1 Margetuximab Patients 963.7 KB Rugo SOPHIA Study ASCO 2019 843.6 KB
May 1, 2019 4:30 PM EDT	MacroGenics, Inc. First Quarter 2019 Financial Results Conference Call Listen to webcast
Mar 31 from 1:00 PM EDT to Apr 3, 2019	Posters at the American Association for Cancer Research (AACR) Annual Meeting 2019 Supporting Materials Tumor-antigen 5T4-dependent Activation of the CD137 Costimulatory Pathway by Bispecific 5T4 x CD137 TRIDENT™ Molecules 2.8 MB Selection of a Bispecific Trivalent HER2 x CD137 TRIDENT™ Format Providing Optimal Tumor-anchored Immune Co-stimulation 974.8 KB Margetuximab Mediates Greater Fc-dependent Anti-tumor Activities than Trastuzumab or Pertuzumab In Vitro 1.3 MB IMGC936, a first in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity 282.9 KB PharmacodynamicCorrelates in a Phase 1 Study of INCMGA00012, a PD-1 Antagonistic Monoclonal Antibody 974.6 KB Assessment of Flat Dosing Strategy for INCMGA00012 in Patients With Advanced Tumors 1.8 MB
Feb 26, 2019 4:30 PM EST	MacroGenics, Inc. Fourth Quarter 2018 Financial Results Conference Call Listen to webcast
Feb 19, 2019	Keystone Symposia Conference Supporting Materials MGD019, a PD-1 x CTLA-4 Bispecific DART® Molecule, Provides Simultaneous Blockade of PD-1 and CTLA-4 Checkpoint Pathways 3.6 MB
Feb 6, 2019 8:30 AM EST	MacroGenics SOPHIA Results Conference Call Listen to webcast
Jan 17, 2019 2:30 PM EST	ASCO GI Cancers Symposium Poster Supporting Materials View Poster 2.5 MB
Dec 8, 2018	Poster presented at 2018 San Antonio Breast Cancer Symposium Supporting Materials Review of Long-term Metastatic HER2+ Breast Cancer Responders to Single-agent Margetuximab 570.4 KB
Dec 2, 2018 9:00 AM PST	Presentations at 60th Annual ASH Meeting regarding Flotetuzumab (CD123 x CD3 DART Molecule): Supporting Materials Phase 1 Data from Cohort Expansion in Patients with R/R AML (Oral) 810.1 KB Management of CRS in AML Patients Treated with Flotetuzumab (Poster) 809.9 KB Adaptive Immune Gene Signatures Correlate w/Response to Flotetuzumab in Patients with R/R AML 2 MB Primary Refractory AML Patient Case Study - Bone Marrow T Cell Changes 3.8 MB
Nov 13, 2018	EORTC-NCI-AACR Symposium 2018 Supporting Materials PD-L1 x CD137 Poster at EORTC-NCI-AACR Meeting 894.2 KB
Nov 9, 2018 5:00 PM EST	Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting Supporting Materials Oral (O24) - Ph. 1 Study of Enoblituzumab + Pembrolizumab Clinical Data (Dr. Charu Aggarwal) 943.3 KB Poster (O24) - Ph. 1 Study of Enoblituzumab + Pembrolizumab Clinical Data 775.2 KB Poster (P669) - Ph. 1 Study of MGA012 (INCMGA00012): Interim Results (Incyte) 340.6 KB Poster (P338) – Ph. 2 Study of Enoblituzumab in Neoadjuvant Prostate (JHU) 1.3 MB Poster (P304) - Ph. 1 Study of MGD007 + MGA012 in R/R Metastatic CRC (TIP) 1.7 MB Poster (P305) - Ph. 1 Study of MGD009 + MGA012 in R/R B7-H3-Expressing Tumors (TIP) 689.3 KB Poster (P306) - Phase 1/2 Study of MGC018 Alone or in Combo w/MGA012 (TIP) 398.6 KB Poster (P366) – MGD009 (Orlotamab) + MGA012 Rationale 1.8 MB